ArticleAntimicrobial resistance and infection control2020
Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
Article in Antimicrobial resistance and infection control, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Emerging pathogens in urinary tract infections: virulence and phenotypic characterization ofmSphere · 2026Article
- Effects of repeated culture in sub-inhibitory concentrations of ciprofloxacin on resistance and genetic characteristics of an ocular Pseudomonas aeruginosa isolate.World journal of microbiology & biotechnology · 2026Article
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Candida tropicalis culture supernatants modulate Pseudomonas aeruginosa antimicrobial resistance and biofilm formation.Scientific reports · 2025Article
- Isolation and characterization of Pseudomonas phage HJ01 and its therapeutic efficacy in canine pyoderma.BMC veterinary research · 2025Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
- Article
- Preliminary insights into the potential role of Acanthamoeba-Pseudomonas interactions in the development of antibiotic resistance.Access microbiology · 2025Article
- Article
- "Pleiotropic" Effects of Antibiotics: New Modulators in Human Diseases.Antibiotics (Basel, Switzerland) · 2024Review
- Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances.Molecular biomedicine · 2024Review
- Navigating fluoroquinolone resistance in Gram-negative bacteria: a comprehensive evaluation.JAC-antimicrobial resistance · 2024Review
- Quorum-sensing regulation of phenazine production heightensAntimicrobial agents and chemotherapy · 2024Article
- Mechanism of Qiguiyin Decoction Sensitizing Levofloxacin Against Multidrug-ResistantInfection and drug resistance · 2024Article
- Recent advances in nanoantibiotics against multidrug-resistant bacteria.Nanoscale advances · 2023Review
- Di-berberine conjugates as chemical probes of Pseudomonas aeruginosa MexXY-OprM efflux function and inhibition.npj antimicrobials and resistance · 2023Article
- Novel Fluoroquinolones with Possible Antibacterial Activity in Gram-Negative Resistant Pathogens: In Silico Drug Discovery.Molecules (Basel, Switzerland) · 2023Article
- Drug Loaded 3D-Printed Poly(ε-Caprolactone) Scaffolds for Local Antibacterial or Anti-Inflammatory Treatment in Bone Regeneration.Polymers · 2023Article
- Di-berberine conjugates as chemical probes ofbioRxiv : the preprint server for biology · 2023Article
- A nosocomial Pseudomonas aeruginosa ST3495 isolated from a wild Burmese python (Python bivittatus) with suppurative pneumonia and bacteremia in Hainan, China.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluoroquinolone resistance in Pseudomonas aeruginosa typically arises through site-specific mutations and overexpression of efflux pumps. In this study, we investigated the dynamics of different resistance mechanisms in P. aeruginosa populations that have evolved under fluoroquinolone pressure, as well as the interactions between these mechanisms in evolutionary trajectories. Bacteria of strain ATCC27853 were selected under different concentrations of ciprofloxacin and levofloxacin for six parallel lineages, followed by amplification of four target genes in the quinolone-resistance determining region (QRDR) and Sanger sequencing to identify the mutations. The expression of four efflux pump proteins was evaluated by real-time polymerase chain reaction using the relative quantitation method, with the ATCC27853 strain used as a control. We found that ciprofloxacin killed P. aeruginosa sooner than did levofloxacin. Further, we identified five different mutations in three subunits of QRDRs, with gyrA as the main mutated gene associated with conferring fluoroquinolone resistance. Additionally, we found a larger number of mutations appearing at 2 mg/L and 4 mg/L of ciprofloxacin and levofloxacin, respectively. Moreover, we identified the main efflux pump being expressed as MexCD-OprJ, with initial overexpression observed at 0.25 mg/L and 0.5 mg/L of ciprofloxacin and levofloxacin, respectively. These results demonstrated gyrA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.